An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia.
Yang J, Surapaneni M, Schiffer CA.
Expert Rev Hematol · review; journal article · DOI 10.1080/17474086.2022.2077187 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för ponatinib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
40 hitsCorrection: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib.
Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E.
Leukemia · published erratum · DOI 10.1038/s41375-022-01568-3Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia.
Haddad FG, Issa GC, Jabbour E, Yilmaz M.
Expert Opin Pharmacother · review; journal article · DOI 10.1080/14656566.2022.2064742Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers.
George S, von Mehren M, Fletcher JA, Sun J, Zhang S, Pritchard JR, Hodgson JG, Kerstein D, Rivera VM, Haluska FG, Heinrich MC.
Clin Cancer Res · clinical trial, phase ii; research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-21-2037Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group.
Kodama Y, Sato A, Kato K, Sakaguchi H, Kato M, Kawasaki H, Hiramatsu H, Kato I, Taga T, Shimada H.
Int J Hematol · journal article · DOI 10.1007/s12185-022-03329-5Synthesis of ponatinib analogues as novel inhibitors of leukemia stem cells.
Wang L, Zhao XJ, Hua C, Wu HX, Bai CG, Chen Y.
Future Med Chem · research support, non-u.s. gov't; journal article · DOI 10.4155/fmc-2022-0038Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model.
Lindström HJG, Friedman R.
Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41598-022-09048-5Combination therapy with low doses of ponatinib and steroids in elderly and frail patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Tsushima T, Sato N, Guo YM, Uchiyama S, Nakamura H, Nagata A, Song-Gi C, Yamauchi N, Minami Y, Yuda J.
Ann Hematol · letter · DOI 10.1007/s00277-022-04796-wINCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia.
Martinelli G, Papayannidis C, Piciocchi A, Robustelli V, Soverini S, Terragna C, Marconi G, Lemoli RM, Guolo F, Fornaro A, Lunghi M, de Fabritiis P, Candoni A, Selleri C, Simonetti F, Bocchia M, Vitale A, Frison L, Tedeschi A, Cuneo A, Bonifacio M, Martelli MP, D'Ardia S, Trappolini S, Tosi P, Galieni P, Fabbiano F, Abbenante MC, Granier M, Zhu Z, Wang M, Sartor C, Paolini S, Cavo M, Foà R, Fazi P, Vignetti M, Baccarani M.
Blood Adv · research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1182/bloodadvances.2021004821Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model.
Madonna R, Pieragostino D, Cufaro MC, Del Boccio P, Pucci A, Mattii L, Doria V, Cadeddu Dessalvi C, Zucchi R, Mercuro G, De Caterina R.
J Cell Mol Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/jcmm.17008Structural study of ponatinib in inhibiting SRC kinase.
Guo M, Duan Y, Dai S, Li J, Chen X, Qu L, Chen Z, Wei H, Jiang L, Chen Y.
Biochem Biophys Res Commun · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbrc.2022.02.001Ponatinib-induced eruptive nevi and melanocytic proliferation.
Kim YH, Kim Y, Park TJ, Kang HY.
Melanoma Res · journal article; case reports · DOI 10.1097/cmr.0000000000000792Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia.
Wang H, Yang C, Shi T, Zhang Y, Qian J, Wang Y, Hu Y, Mao L, Ye X, Liu F, Xi Z, Shou L, Fu C, Naranmandura H, Jin J, Zhu HH.
Blood Cancer J · letter; research support, non-u.s. gov't · DOI 10.1038/s41408-022-00621-9Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis.
Kayabasi C, Caner A, Yilmaz Susluer S, Balci Okcanoglu T, Ozmen Yelken B, Asik A, Mutlu Z, Caliskan Kurt C, Goker Bagca B, Biray Avci C, Sahin F, Saydam G, Gunduz C.
Med Oncol · journal article · DOI 10.1007/s12032-021-01629-0Ponatinib, Lestaurtinib, and mTOR/PI3K Inhibitors Are Promising Repurposing Candidates against Entamoeba histolytica.
Kangussu-Marcolino MM, Singh U.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1128/aac.01207-21Bowel Perforation Secondary to Ponatinib Treatment in a Chronic Myelogenous Leukemia Patient: A Case Report.
Sallam A, Gmati GE, Salman R.
Cureus · journal article; case reports; case-report · DOI 10.7759/cureus.19949Receptor-Tyrosine Kinase Inhibitor Ponatinib Inhibits Meningioma Growth In Vitro and In Vivo.
Yu T, Cao J, Alaa Eddine M, Moustafa M, Mock A, Erkut C, Abdollahi A, Warta R, Unterberg A, Herold-Mende C, Jungwirth G.
Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers13235898Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring <i>KRAS</i> Mutations.
Arbour KC, Manchado E, Bott MJ, Ahn L, Tobi Y, Ni AA, Yu HA, Shannon A, Ladanyi M, Perron V, Ginsberg MS, Johnson A, Holodny A, Kris MG, Rudin CM, Lito P, Rosen N, Lowe S, Riely GJ.
JTO Clin Res Rep · brief-report; journal article · DOI 10.1016/j.jtocrr.2021.100256Taming the gatekeeper: ponatinib dose holds the key.
Branford S.
Blood · comment; editorial · DOI 10.1182/blood.2021013284Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
Kawano N, Kimura S, Miura M, Tochigi T, Nakaike T, Yamashita K, Mashiba K, Kikuchi I, Takahashi N.
Int J Hematol · journal article; case reports · DOI 10.1007/s12185-021-03186-8Ponatinib-Associated Cardiac Tamponade.
Lee JE, Ghous G, Tarar ZI, Zafar MU, Hassan Shoukat HM.
Am J Ther · letter · DOI 10.1097/mjt.0000000000001353Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations.
Choi JP, Wang R, Yang X, Wang X, Wang L, Ting KK, Foley M, Cogger V, Yang Z, Liu F, Han Z, Liu R, Baell J, Zheng X.
Sci Adv · research support, non-u.s. gov't; research-article; journal article · DOI 10.1126/sciadv.aau0731Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI, Dorer DJ, Davis J, Turner CD, Marbury TC, Sonnichsen D.
Cancer Chemother Pharmacol · comparative study; clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-014-2511-zClinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.
Ferri CA, Bianchini M, Bengió RM, Moiraghi EB, Gonzalez MS, Noriega MF, Larripa IB.
Eur J Haematol · research support, non-u.s. gov't; journal article; case reports · DOI 10.1111/ejh.12358Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Hoy SM.
Drugs · review; journal article · DOI 10.1007/s40265-014-0216-6Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
Canning P, Tan L, Chu K, Lee SW, Gray NS, Bullock AN.
J Mol Biol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.jmb.2014.04.014Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⁺ pre-B acute lymphoblastic leukaemia.
Robinson S, Levy Y, Maisel C, Tong AW.
BMJ Case Rep · journal article; case reports; case-report · DOI 10.1136/bcr-2014-203894Ponatinib-induced neutrophilic panniculitis.
Zhang M, Hassan KM, Musiek A, Rosman IS.
J Cutan Pathol · journal article; case reports · DOI 10.1111/cup.12326The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.
Ray S, Bender S, Kang S, Lin R, Glicksman MA, Liu M.
J Biol Chem · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1074/jbc.m113.537811Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Okabe S, Tauchi T, Kimura S, Maekawa T, Kitahara T, Tanaka Y, Ohyashiki K.
PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0089080